Updated: Akero redeems its failure in severe MASH with longer-term data
Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% benefit on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.